Analysis Of Subcutaneous Furosemide Dosing Patterns And Impact On SCr And K+ In The Freedom-HF And AT HOME Studies

Daniel Bensimhon,James Udelson,Tamas Alexy,Katie Luepke,Matthew Goodwin,Phani Kamineni,John Mohr,Marvin Konstam

DOI: https://doi.org/10.1016/j.cardfail.2023.10.169

IF: 6.592

2024-01-01

Journal of Cardiac Failure

Abstract:Introduction Furoscix is a 80mg/10mL buffered formulation of furosemide developed for subcutaneous self-administration in the outpatient setting via a wearable, pre-programmed infusor over 5 hours. In the FREEDOM-HF observational study and the AT HOME-HF randomized trial, patients received Furoscix at study entry, transitioned back to oral diuretics when clinically indicated and were followed for 30 days. The objective of this analysis was to describe Furoscix dosing patterns and associated short-term changes in renal function (SCr) and potassium level (K+). Methods Both studies enrolled hemodynamically stable patients with NYHA Class II-IV chronic HF with worsening signs and symptoms of congestion requiring augmented diuresis (FREEDOM-HF in ED before discharge, AT-HOME HF as outpatient). Changes from baseline in SCr and K+ were assessed in both trials at Day 3, and incidence of worsening renal function (WRF) (> 25% increase in SCr) and hypokalemia (mild: K+<3.5 mg/dL; moderate: K+<3.0 mg/dL) were captured. Results were stratified based on number of Furoscix doses administered and baseline daily total oral furosemide equivalent dosage (<120 mg or >120 mg). Results A total of 58 patients were included, 24 from FREEDOM-HF and 34 from AT-HOME. The mean (range) number of per patient doses over the study duration was 6 (2-10) in FREEDOM-HF and 4 (1-9) in AT-HOME. All patients received at least one Furoscix dose within 3 days of enrollment; 11 received 1 dose and 47 two or more doses. 83% of total Furoscix doses administered in the 30-day study period were administered within the first 7 days, and 61% were administered within the first 3 days. Twice daily dosing was utilized < 5% of study days. At baseline, 38% of patients had Stage 2 CKD (n=22) followed by Stages 3A and 3B (n=13, 24% for each). Mean increase in SCr was 0.11±0.2 mg/dL; 5 (9%) patients experienced WRF (2 patients after 1 dose, 2 patients after 3 doses and 1 patient after 4 doses). All cases of WRF resolved spontaneously and/or with transient holding of diuretics. Overall, serum K+ increased by a mean of 0.01±0.6 mg/dL. 5 patients (9%) developed hypokalemia during the first 3 days; 4 mild and 1 moderate. 35 patients (60%) received K+ with their Furoscix dosing. Neither the number of Furoscix doses nor baseline furosemide equivalent dose had a statistically significant impact on change in SCr or K+. Conclusions Across both studies, over 80% of Furoscix doses were administered within the first 7 days and over 60% were administered within the first 3 days. At day 3 (first clinic visit in both trials), the incidence of hypokalemia and worsening renal function was <10% and was not related to number of Furoscix doses given or baseline renal function.

cardiac & cardiovascular systems